Fortress Biotech
Market Cap
US$244.9m
Last Updated
2020/06/06 05:01 UTC
Data Sources
Company Financials +
Executive Summary
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has Fortress Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FBIO's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
2.4%
FBIO
-1.5%
US Biotechs
3.8%
US Market
1 Year Return
83.3%
FBIO
22.1%
US Biotechs
9.7%
US Market
Return vs Industry: FBIO exceeded the US Biotechs industry which returned 22.1% over the past year.
Return vs Market: FBIO exceeded the US Market which returned 9.7% over the past year.
Shareholder returns
| FBIO | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.4% | -1.5% | 3.8% |
| 30 Day | 42.1% | 3.5% | 11.4% |
| 90 Day | 48.5% | 9.0% | 6.8% |
| 1 Year | 83.3%83.3% | 23.3%22.1% | 12.1%9.7% |
| 3 Year | -33.0%-33.0% | 26.1%22.1% | 36.2%27.2% |
| 5 Year | -3.9%-3.9% | -5.5%-11.0% | 63.7%45.4% |
Price Volatility Vs. Market
How volatile is Fortress Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Could The Fortress Biotech, Inc. (NASDAQ:FBIO) Ownership Structure Tell Us Something Useful?1 month ago | Simply Wall St
Analysts Expect Breakeven For Fortress Biotech, Inc. (NASDAQ:FBIO)2 months ago | Simply Wall St
Analysts Just Made A Captivating Upgrade To Their Fortress Biotech, Inc. (NASDAQ:FBIO) ForecastsValuation
Is Fortress Biotech undervalued compared to its fair value and its price relative to the market?
6.27x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate FBIO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate FBIO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: FBIO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: FBIO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FBIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FBIO is overvalued based on its PB Ratio (6.1x) compared to the US Biotechs industry average (3.6x).
Next Steps
Future Growth
How is Fortress Biotech forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
75.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FBIO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: FBIO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: FBIO's is expected to become profitable in the next 3 years.
Revenue vs Market: FBIO's revenue (37% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: FBIO's revenue (37% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FBIO's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Fortress Biotech performed over the past 5 years?
-6.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FBIO is currently unprofitable.
Growing Profit Margin: FBIO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FBIO is unprofitable, and losses have increased over the past 5 years at a rate of -6.8% per year.
Accelerating Growth: Unable to compare FBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: FBIO has a negative Return on Equity (-145.41%), as it is currently unprofitable.
Next Steps
Financial Health
How is Fortress Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: FBIO's short term assets ($158.8M) exceed its short term liabilities ($51.7M).
Long Term Liabilities: FBIO's short term assets ($158.8M) exceed its long term liabilities ($101.7M).
Debt to Equity History and Analysis
Debt Level: FBIO's debt to equity ratio (120.2%) is considered high.
Reducing Debt: FBIO's debt to equity ratio has increased from 39.9% to 120.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FBIO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FBIO has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 28.6% each year.
Next Steps
Dividend
What is Fortress Biotech's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FBIO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.5yrs
Average management tenure
CEO
Lindsay Rosenwald (64yo)
6.5yrs
Tenure
US$1,090,016
Compensation
Dr. Lindsay Allan Rosenwald, M.D., serves as the Chairman of the Board of Directors at Avenue Therapeutics, Inc since February, 2015. He has been Executive Chairman, Chief Executive Officer and President o ...
CEO Compensation Analysis
Compensation vs Market: Lindsay's total compensation ($USD1.09M) is about average for companies of similar size in the US market ($USD1.30M).
Compensation vs Earnings: Lindsay's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.5yrs | US$1.09m | 12.02% $29.4m | |
| Vice Chairman & Executive Vice Chairman of Strategic Development | 6.33yrs | US$1.09m | 12.37% $30.3m | |
| CFO, Treasurer & Corporate Secretary | 3yrs | US$1.80m | 0.12% $284.0k | |
| Senior Vice President of Biologics Operations | 7yrs | US$386.35k | 0.79% $1.9m | |
| Project Leader of Inflammatory Bowel Disease | 7.08yrs | no data | no data |
6.5yrs
Average Tenure
60.5yo
Average Age
Experienced Management: FBIO's management team is seasoned and experienced (6.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.5yrs | US$1.09m | 12.02% $29.4m | |
| Vice Chairman & Executive Vice Chairman of Strategic Development | 6.33yrs | US$1.09m | 12.37% $30.3m | |
| Independent Director | 6.33yrs | US$78.00k | 0.10% $252.4k | |
| Independent Director | 4.92yrs | US$146.00k | 0.14% $346.9k | |
| Co-Vice Chairman | 9.67yrs | US$278.50k | 0.79% $1.9m | |
| Independent Director | 14yrs | US$153.50k | 1.26% $3.1m | |
| Scientific Advisor | 3yrs | no data | no data | |
| Scientific Advisor | 3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 11.5yrs | US$133.50k | 0.061% $148.5k |
6.3yrs
Average Tenure
63yo
Average Age
Experienced Board: FBIO's board of directors are considered experienced (6.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.4%.
Top Shareholders
Company Information
Fortress Biotech, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Fortress Biotech, Inc.
- Ticker: FBIO
- Exchange: NasdaqCM
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$244.948m
- Shares outstanding: 82.47m
- Website: https://www.fortressbiotech.com
Number of Employees
Location
- Fortress Biotech, Inc.
- 2 Gansevoort Street
- 9th Floor
- New York
- New York
- 10014
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| FBIO | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Nov 2011 |
| CNB | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 2011 |
| FBIO.P | NasdaqCM (Nasdaq Capital Market) | 9.375% CUM PFD A | US | USD | Nov 2017 |
Biography
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. It markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ala-Scalp and Triderm, which are used for the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and Ala-Quin, an antibacterial and antifungal cream. The company also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial that reduces amyloid deposits in the tissues and organs; CD123 chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; CD20 CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, it develops MB-101 for Glioblastoma (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101, a Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; CK-301, a Phase I clinical trial for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; Tamid-001, a gene therapy for mucopolysaccharidosis type I disorder; CNDO-109, a lysate that activates donor natural killer cells; and methazalomide products. The company has collaboration arrangements with some universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/06 05:01 |
| End of Day Share Price | 2020/06/05 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.